Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
— Nestlé Health Science to Make Investment through the Purchase of Nearly 7.6 Million Shares of Aimmune Stock at $19.20 per Share — — Companies Enter into Strategic Collaboration Agreement Designed to Enable the Successful Development and Commercialization of Innovative Food Allergy Therapies — —
Toggle Summary Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— PALISADE Completed in 2017; Topline Results Anticipated in February — — Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy , Asthma & Immunology–World Allergy Organization Joint Congress in March — — PALISADE Follow-On Study, ARC004, Fully Enrolled — — RAMSES Real-World
Toggle Summary Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas , M.D., will give his first public presentation as the company’s President and CEO
Toggle Summary Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
— Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients — — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment — — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m.
Toggle Summary Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 11, 2015-- Aimmune Therapeutics, Inc. , today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the
Toggle Summary Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 26, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the completion of its previously announced underwritten public offering of 5,500,000
Toggle Summary Aimmune Therapeutics Announces COO Transition
— COO Howard Raff to Retire from Leadership Position to Focus on Future Pipeline Development — — Aimmune Builds Clinical Team with Key Allergist / Immunologist Hires — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 9, 2015-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018
— In U.S. Survey , Allergists Want Consensus in Oral Immunotherapy Terminology — — U.S. Allergists Preferred “Tolerated Dose” as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients — BRISBANE, Calif. & MUNICH, Germany --(BUSINESS WIRE)--May 29,
Toggle Summary Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 2, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten public offering of 5,500,000
Toggle Summary Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months ended September 30, 2015 .